Dr. Reddy's Laboratories

Dr. Reddy's Recalls Prescription Drug Blister Packages Due to Risk of Poisoning

Retrieved on: 
Thursday, February 25, 2021
Health sciences, Health care, Health, Clinical pharmacology, Symbols, Pharmaceuticals policy, Drugs, Prescription drug, Pharmacy, Dr. Reddy's Laboratories, Medical prescription, Packaging and labeling

The prescription medications were distributed by third party wholesalers to retail pharmacies and could have been dispensed to consumers.

Key Points: 
  • The prescription medications were distributed by third party wholesalers to retail pharmacies and could have been dispensed to consumers.
  • The packaging of the products is not child resistant and can pose a risk of poisoning if the contents are swallowed by young children.
  • Consumers should immediately store the recalled medications in a safe location out of reach of children and contact Dr. Reddy's for a full refund.
  • This recall involves blister packages of prescription medications.

Dr. Reddy's Laboratories Announces the Launch of Lansoprazole DR Orally Disintegrating Tablets in the U.S. Market

Retrieved on: 
Monday, February 22, 2021
Biotechnology, General Health, Other Health, Health, Pharmaceutical, Companies, Health care, Health sciences, Pharmaceuticals policy, NIFTY 50, Benzimidazoles, Dr. Reddy's Laboratories, Orally disintegrating tablet, Generic drug, Takeda Pharmaceutical Company, Lansoprazole, Pharmaceutical industry in China

Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as Dr. Reddys) today announced the launch of Lansoprazole DR Orally Disintegrating Tablets, a therapeutic equivalent generic version of Prevacid SoluTab Delayed-Release Orally Disintegrating Tablets, 15 mg and 30 mg, approved by the U.S. Food and Drug Administration (USFDA).

Key Points: 
  • Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as Dr. Reddys) today announced the launch of Lansoprazole DR Orally Disintegrating Tablets, a therapeutic equivalent generic version of Prevacid SoluTab Delayed-Release Orally Disintegrating Tablets, 15 mg and 30 mg, approved by the U.S. Food and Drug Administration (USFDA).
  • The Prevacid brand and generic had U.S. sales of approximately $87 million MAT for the most recent twelve months ending in December 2020 according to IMS Health*.
  • https://www.drreddys.com/pi/lansoprazoledr_odtus_outsert_v_3.pdf
    Prevacid is a trademark of Takeda Pharmaceuticals U.S.A., Inc.
    About Dr. Reddys: Dr. Reddys Laboratories Ltd. ((BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is an integrated pharmaceutical company committed to providing affordable and innovative medicines for healthier lives.
  • Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology.

Dr. Reddy's Initiates Process for Emergency Use Authorization of Sputnik V

Retrieved on: 
Friday, February 19, 2021
Infectious diseases, Pharmaceutical, Health, Other Health, Clinical trials, Mass media, COVID-19 pandemic in Russia, Science and technology in Russia, Sputnik V COVID-19 vaccine, Health care, Medicine, Dr. Reddy's Laboratories, Sputnik, The Lancet

In September 2020, Dr. Reddys partnered with the Russian Direct Investment Fund (RDIF) to conduct the clinical trials of the Sputnik V and for its distribution rights in India.

Key Points: 
  • In September 2020, Dr. Reddys partnered with the Russian Direct Investment Fund (RDIF) to conduct the clinical trials of the Sputnik V and for its distribution rights in India.
  • Sputnik V maintained a consistent efficacy at 91.8% even among the group of 2,144 volunteers over 60 years old.
  • G V Prasad, Co-chairman and Managing Director, Dr. Reddys Laboratories, said, The efficacy of Sputnik V was reported to be 91.6 % by the Lancet, which is an impressive development in the fight against COVID-19.
  • The initiation of the EUA process will be a critical step forward for us in ensuring speedy access to the Sputnik V vaccine in India.

United States Breast Cancer Drug Market, Drug Price, Dosage & Clinical Trials Insights 2026 - ResearchAndMarkets.com

Retrieved on: 
Friday, January 22, 2021
Pharmaceutical, Health, Oncology, Health sciences, Health, Life sciences, Breast cancer, Medication, Cancer, Pharmaceutical industry, Breast cancer research stamp, Dr. Reddy's Laboratories

The "US Breast Cancer Drug Market, Drug Price, Dosage & Clinical Trials Insight 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "US Breast Cancer Drug Market, Drug Price, Dosage & Clinical Trials Insight 2026" report has been added to ResearchAndMarkets.com's offering.
  • Breast cancer therapeutics market in the US represents itself as a paralleled contributor to the total pharmaceutical market in the country.
  • "US Breast Cancer Drug Market, Drug Price, Dosage & Clinical Trials Insight 2026" Report Highlights:
    US Breast Cancer Drug Market: > USD 20 Billion Opportunity by 2026
    US Breast Cancer clinical Trials: 350 Drugs in Pipeline
    Marketed Breast Cancer Drugs Dosage, Patent & Pricing
    6.
  • Alkylating Agents for Breast Cancer - US Market Availability, Dosage, Patent & Price Insight
    18.

Dr. Reddy’s Receives Approval to Conduct Phase 3 Clinical Trial for Sputnik V Vaccine in India

Retrieved on: 
Friday, January 15, 2021
Infectious diseases, Pharmaceutical, Health, Clinical trials, Health sciences, Health, COVID-19 pandemic in Russia, Gam-COVID-Vac, Science and technology in Russia, Clinical research, Design of experiments, Dr. Reddy's Laboratories, Drugs Controller General of India, DSMB, Clinical trial

Dr. Reddys Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) announced today that it has received approval from the Drugs Control General of India (DCGI) to conduct phase 3 clinical trial for the Sputnik V vaccine in India.

Key Points: 
  • Dr. Reddys Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) announced today that it has received approval from the Drugs Control General of India (DCGI) to conduct phase 3 clinical trial for the Sputnik V vaccine in India.
  • Earlier, the Data and Safety Monitoring Board (DSMB) reviewed the safety data from the phase 2 clinical trial of the vaccine and recommended the phase 3 recruitment.
  • G V Prasad, Co-chairman and Managing Director, Dr. Reddys Laboratories said, This is an important milestone in the progress of this pivotal clinical trial of the vaccine.
  • In September 2020, Dr. Reddys partnered with Russian Direct Investment Fund (RDIF) to conduct the clinical trials of the Sputnik V vaccine and for its distribution rights in India.

Sputnik V meets the primary endpoint of safety in the Phase 2 Clinical Trial in India

Retrieved on: 
Monday, January 11, 2021
Infectious diseases, Pharmaceutical, Health, Clinical trials, Health sciences, Health, Clinical research, Design of experiments, Clinical trials, COVID-19 pandemic in Russia, Gam-COVID-Vac, Science and technology in Russia, Kirill Dmitriev, Dr. Reddy's Laboratories, Placebo-controlled study, Drugs Controller General of India

The phase 2 study of Sputnik V was conducted on 100 subjects as part of the randomized, double-blind, parallel-group, placebo-controlled study in India.

Key Points: 
  • The phase 2 study of Sputnik V was conducted on 100 subjects as part of the randomized, double-blind, parallel-group, placebo-controlled study in India.
  • Further, the safety data has been submitted to the Drugs Controller General of India (DCGI) for review and approval to continue phase 3 clinical trials.
  • G V Prasad, Co-chairman and Managing Director, Dr. Reddys Laboratories said, The Indian clinical trial being conducted by Dr. Reddys and RDIF is an adaptive design phase 2/3 trial.
  • Kirill Dmitriev, CEO of the Russian Direct Investment Fund, said, The safety data from the phase 2 clinical trial from India is very positive, and confirms the safety profile of Sputnik V in the international markets.

Dr. Reddy's Laboratories announces the launch of Febuxostat Tablets in the U.S. Market

Retrieved on: 
Monday, January 11, 2021
Biotechnology, FDA, Pharmaceutical, Health, Companies, Chemical compounds, Pharmaceutical companies, Febuxostat, Nitriles, Thiazoles, NIFTY 50, Dr. Reddy's Laboratories, IQVIA, Medication

Consider the risks and benefits of Febuxostat when deciding to prescribe or continue patients on Febuxostat.

Key Points: 
  • Consider the risks and benefits of Febuxostat when deciding to prescribe or continue patients on Febuxostat.
  • *IQVIA Retail and Non-Retail MAT October 2020.
  • About Dr. Reddys: Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives.
  • Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology.

The Pharmaceutical Industry in South Africa 2020 - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 31, 2020
Health, Pharmaceutical, Health care, Health sciences, Health, Pharmaceuticals policy, Pharmaceutical industry in China, Pharmacy in China, Science and technology in the People's Republic of China, Pharmaceutical industry in India, Pharmaceutical industry, Dishman Pharmaceuticals and Chemicals, Dr. Reddy's Laboratories

"The Pharmaceutical Industry in South Africa 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • "The Pharmaceutical Industry in South Africa 2020" report has been added to ResearchAndMarkets.com's offering.
  • The pharmaceutical sector is dominated by multinational pharmaceutical companies.
  • While almost 70% of the pharmaceutical products that are used are locally-produced, various active pharmaceutical ingredients and finished products are imported.
  • This report focuses on the manufacture of pharmaceuticals in South Africa and includes the wholesale and retail trade in pharmaceutical products.

Secondary Listing of Dr. Reddy’s ADRs on NSE IFSC Limited (GIFT City, Gujarat, India)

Retrieved on: 
Wednesday, December 9, 2020
Oncology, Professional services, Health, Finance, General Health, Pharmaceutical, Banking, Finance, Financial markets, Money, Depositary receipts, American depositary receipt, Stock market, NIFTY 50, Economy of Gujarat, Cross listing, National Stock Exchange of India, Gujarat International Finance Tec-City, Dr. Reddy's Laboratories

Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY referred to as Dr. Reddys) today announced the secondary listing of its American Depository Receipts (ADRs) on NSE IFSC Limited under the symbol DRREDDY on December 9, 2020.

Key Points: 
  • Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY referred to as Dr. Reddys) today announced the secondary listing of its American Depository Receipts (ADRs) on NSE IFSC Limited under the symbol DRREDDY on December 9, 2020.
  • NSE IFSC Limited is a recognized international stock exchange established in the International Financial Services Centre (IFSC), GIFT City Gujarat, India.
  • The said listing will provide a secondary platform (other than NYSE Inc.) to overseas investors for trading in Dr. Reddys ADRs.
  • This is a secondary listing of ADRs that are currently issued by J.P. Morgan Chase Bank N.A.

Slayback Pharma Appoints Dr Sumitra Pillai as Head of R&D

Retrieved on: 
Monday, December 7, 2020
Fictional characters, Slayback, Dr. Reddy's Laboratories, Pillai, Companies

PRINCETON, N.J., Dec. 7, 2020 /PRNewswire/ --Slayback Pharma LLC ("Slayback") announced today the appointment of Dr Sumitra Pillai as Vice President and the new Head of R&D.

Key Points: 
  • PRINCETON, N.J., Dec. 7, 2020 /PRNewswire/ --Slayback Pharma LLC ("Slayback") announced today the appointment of Dr Sumitra Pillai as Vice President and the new Head of R&D.
  • Sumitra is a highly accomplished scientist with a stellar track record in the development and scale-up of highly complex, differentiated and difficult-to-make generics.
  • Prior to joining Slayback, Sumitra was the Vice President of Research and Development at Dr. Reddy's Laboratories where she was instrumental in successful development of numerous complex injectables and ophthalmic products.
  • While welcoming Dr Pillai to Slayback, Ajay Singh, President & CEO, said, "Sumitra is a perfect fit for Slayback.